Drug–drug interactions (DDIs) are an emerging threat to public health. Recent estimates
indicate that DDIs cause nearly 74000 emergency room visits and 195000 hospitalizations …

This article reviews in vitro metabolic and in vivo pharmacokinetic drug–drug interactions of
nine antifungal agents: six azoles (fluconazole, itraconazole, ketoconazole, miconazole …

This is the fourth set of Handbook of Porphyrin Science. Porphyrins, phthalocyanines and
their numerous analogues and derivatives are materials of tremendous importance in …

Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and
because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is …

Human liver microsomes have typically resulted in marked underprediction of in vivo human
intrinsic clearance (CLint); therefore, the utility of cryopreserved hepatocytes as an …

Abstract Background and Objective The identification and quantification of potential drug–
drug interactions is important for avoiding or minimizing the interaction-induced adverse …

Abstract Background Cytochrome P450 (CYP) 3A4 is the most prevalent metabolising
enzyme in the human liver and is also a target for various drug interactions of significant …

Drug–drug interactions (DDIs) caused by the co‐administration of multiple drugs are major
safety concerns in the clinic. Several drugs have been withdrawn from the market due to …

Current assessment of drug-drug interaction (DDI) prediction success is based on whether
predictions fall within a two-fold range of the observed data. This strategy results in a …

Strategies for optimising in vivo predictions from in vitro data on metabolic stability and CYP
inhibition are discussed. Potential pitfalls and areas of inaccuracy are highlighted together …